Nootropic Peptides

For laboratory and research use only — not for human consumption. All content is educational.
Head to head

Semax vs N-Acetyl Semax Amidate

The parent-analogue comparison is one of the most common questions in Semax research contexts. N-Acetyl Semax Amidate ("NA-Semax") is chemically the same core heptapeptide as Semax, but with the N-terminal methionine acetylated and the C-terminal proline amidated. Both modifications block the aminopeptidase and carboxypeptidase attack pathways that clear the parent Semax rapidly from plasma. The result is a molecule with identical pharmacology but substantially better pharmacokinetics — and a much thinner evidence base to draw on.

At a glance

SemaxN-Acetyl Semax
Molecular structureFree N-terminus + free C-terminus, MEHFPGP heptapeptideN-acetyl protected + C-amidated MEHFPGP heptapeptide
SequenceMet-Glu-His-Phe-Pro-Gly-ProAc-Met-Glu-His-Phe-Pro-Gly-Pro-NH₂
Molecular weight813.93 g/mol~869 g/mol (with terminal modifications)
Plasma half-lifeMinutes (parent peptide)Several-fold longer (approximately 3–4× parent)
Pharmacodynamic action24h+ effect on BDNF/NGF from single doseLonger, more sustained BDNF/NGF exposure per dose
Typical dosing frequency2–3× daily in Russian protocols1–2× daily in published research
Evidence baseDeep — Russian clinical use since 1994, multiple RCTsSparser — analogue-specific data is thinner
Clinical approvalApproved in Russia for cerebrovascular indicationsNo clinical approval; research chemical
RouteIntranasal (primary)Intranasal (primary)
Evidence tierAC (limited human data specific to analogue)
UK statusResearch chemicalResearch chemical

The engineering rationale

Why the terminal modifications matter

Semax is efficiently degraded in plasma by two enzyme families. Aminopeptidases attack the free α-amine at the N-terminus, sequentially removing amino acids from the front of the peptide. Carboxypeptidases attack the free carboxylate at the C-terminus, sequentially removing amino acids from the back. Both attacks together give parent Semax a plasma half-life of only minutes.

The N-terminal acetyl group and C-terminal amide of N-Acetyl Semax Amidate block both attacks. The acetyl group removes the free α-amine that aminopeptidases require as a substrate; the amide removes the free carboxylate that carboxypeptidases require. The internal peptide bonds remain susceptible to endopeptidase cleavage, but this is a slower and rate-limited process rather than the rapid terminal trimming that dominates parent Semax clearance.

The result is a molecule with identical receptor pharmacology (the terminal residues don't interact with the mechanism) but substantially longer duration of action per dose. In practical research terms, that means fewer daily doses for equivalent pharmacodynamic effect and better adherence in long protocols.

When to choose which

Practical selection guidance

Choose parent Semax when

The research design benefits from a peak-and-clear pharmacokinetic profile (single acute dose followed by clearance before the next), the protocol length is short enough that dosing frequency doesn't create adherence problems, deep clinical evidence base is important (Semax has a much larger published trial database), or cost is a factor (parent Semax is typically less expensive per dose).

Choose N-Acetyl Semax when

The research design benefits from sustained rather than pulsatile exposure, dosing frequency creates practical adherence problems, the protocol runs long enough that administration convenience matters, or the pharmacodynamic endpoint is one that scales with total exposure (AUC) rather than peak concentration.

The evidence-base tradeoff

The main hesitation about N-Acetyl Semax is that its analogue-specific evidence base is thinner than parent Semax's — for a research design where clinical translation is important, parent Semax has the trial history behind it. For pure research-tool use where the pharmacokinetic profile matters more than the trial-database depth, the analogue is a defensible choice.

Combination with Selank

Either Semax or N-Acetyl Semax can be combined with either Selank or N-Acetyl Selank. The most-common Russian stack pairs parent Semax with parent Selank (both in the 1990s clinical-approval evidence base); the "next-generation" stack pairs N-Acetyl Semax with N-Acetyl Selank for the extended-duration profile. The mechanistic logic is identical in both cases.